$MOLN

Molecular Partners (SIX, NASDAQ: MOLN) reported H1 2026 results, highlighting progress in its Phase 1/2a trial for MP0712, a DLL3-targeting Radio-DARPin, which has advanced to higher dose levels. The company has CHF 67.9M in cash, expected to fund operations into late 2027. Initial data for MP0712 is anticipated in 2026, with efficacy data in 2027. CD70 was selected as a new target for kidney cancer treatment, with clinical programs starting in 2027.

Molecular Partners AG (MOLN) said its Phase 2 TACTIC trial is ongoing in France to test MP0317 plus durvalumab and gemcitabine-cisplatin versus SoC alone in advanced cholangiocarcinoma. The study plans 75 patients, with 9 sites active. Data are expected in 2027 and completion in 2028. MOLN shares closed at $3.91.

Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) said it has dosed first patients in its Phase 2 TACTIC trial of MP0317 plus durvalumab and gemcitabine-cisplatin for advanced cholangiocarcinoma. The randomized study targets 75 patients, with nine sites recruiting. Data are expected in 2027 and completion in 2028; an ESMO 2026 poster is planned.

Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) presented Radio-DARPin approaches at the Gordon Research Conference on radionuclide theranostics, focusing on multispecific designs to address tumor heterogeneity. The company said lead candidates include MP0712 (DLL3) in a multicenter US Phase 1/2a trial and MP0726 (mesothelin) aiming for first human imaging in 2026.

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) updated its targeted alpha Radio-DARPin pipeline. MP0712 (212Pb, DLL3) dosing is ongoing in a US Phase 1/2a study; initial data expected in coming months and more complete safety/efficacy in 2027. MP0726 (MSLN) imaging planned H2 2026; two INDs planned in 2027.

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) updated its targeted alpha Radio-DARPin pipeline. Phase 1/2a dosing is ongoing for MP0712 (DLL3; 212Pb) in a US multicenter study with initial data expected in coming months and fuller safety/efficacy in 2027. FIH imaging for MP0726 (MSLN; planned) starts H2 2026; two INDs and a new target nomination are planned for 2027/2H 2026.

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) and Orano Med said first patients were dosed in a US Phase 1/2a trial of DLL3-targeting 212Pb Radio-DARPin MP0712. Five US sites are recruiting; dosing is ongoing in cohort 1 with repeat dosing. Initial data are expected in 2026 and fuller safety/efficacy in 2027 (NCT07278479).

Case study with first patient images of half-life engineered MP0712 from compassionate care use show specific uptake in primary tumors and metastatic lesions MP0712 Radio-DARPin leverages rapid internalization & replenishment of DLL3 to achieve high accumulation in tumor cells

Poster presentation outlines potential of CD3 Switch-DARPin T cell engager ( TCE ) using an AND-gate to overcome limitations of other TCEs Demonstrated selective T cell cytotoxicity against cells co-expressing tumor-associated antigens MSLN and EpCAM

Molecular Partners's MOLN short percent of float has fallen 5.56% since its last report. The company recently reported that it has 30 thousand shares sold short, which is 0.17% of all regular shares that are available for trading.